Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-244X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study ; volume:22 ; number:1 ; day:28 ; month:5 ; year:2022 ; pages:1-16 ; date:12.2022
BMC psychiatry ; 22, Heft 1 (28.5.2022), 1-16, 12.2022
- Urheber
-
Llorca, Pierre-Michel
Nuss, Philippe
Fakra, Éric
Alamome, Isabelle
Drapier, Dominique
El Hage, Wissam
Jardri, Renaud
Mouchabac, Stéphane
Rabbani, Marc
Simon, Nicolas
Vacheron, Marie-Noëlle
Azorin, Jean-Michel
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12888-022-04008-9
- URN
-
urn:nbn:de:101:1-2022081621490395587072
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Llorca, Pierre-Michel
- Nuss, Philippe
- Fakra, Éric
- Alamome, Isabelle
- Drapier, Dominique
- El Hage, Wissam
- Jardri, Renaud
- Mouchabac, Stéphane
- Rabbani, Marc
- Simon, Nicolas
- Vacheron, Marie-Noëlle
- Azorin, Jean-Michel
- SpringerLink (Online service)
Ähnliche Objekte (12)
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)
The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Predictors of dopamine agonist resistance in prolactinoma patients
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)
The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Predictors of dopamine agonist resistance in prolactinoma patients
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)
The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole
Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
Dopamine agonist resistant prolactinomas: any alternative medical treatment?
Predictors of dopamine agonist resistance in prolactinoma patients
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study